

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Liu Y, Ide Y, Inuzuka M, Tazawa S, Kanada Y, Matsunaga Y, Kuwayama T, Sawada T, Akashi-Tanaka S, Nakamura S.	BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.	Mol Genet Genomic Med	7	e493	2019
Murakami W, Tozaki M, Nakamura S, Ide Y, Inuzuka M, Hirota Y, Murakami K, Takahama N, Ohgiya Y, Gokan T.	The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan.	Breast Cancer		Feb 28. [Epub ahead of print]	2019
Kamitani T, Yabuuchi H, Kanemaki Y, Tozaki M, Sonomura T, Mizukoshi W, Nakata W, Shimono T, Urano M, Yamano T, Kato F, Kuchiki M, Shiraga N, Yanagita H, Katsuda E, Kataoka M, Yamaguchi K, Horikoshi T, Gomi T, Nozaki M, Shiotani M, Amano M, Saigusa H, Sadaoka S, Kamiya H, Kubo M, Yamashita N, Yamamoto H, Honda H.	Effects of menstrual cycle on background parenchymal enhancement and detectability of breast cancer on dynamic contrast-enhanced breast MRI: A multicenter study of an Asian population.	Eur J Radiol	110	130-135	2019
Momozawa Y, Iwasaki Y, Parsons MT, Kamatani Y, Takahashi A, Tamura C, Katagiri T, Yoshida T, Nakamura S, Sugano K, Miki Y, Hirata M, Matsuda K, Spurdle AB, Kubo M.	Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls.	Nat Commun	9	4083	2018
Arai M, Yokoyama S, Watanabe C, Yoshida R, Kita M, Okawa M, Sakurai A, Sekine M, Yotsumoto J, Nomura H, Akama Y, Inuzuka M, Nomizu T, Enomoto T, Nakamura S.	Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan.	J Hum Genet	63	447-457	2018

Machida Y, Shimauchi A, Okuma H, Tozaki M, Isobe S, Fukuma E.	Shear Wave Speed of the Lesion in Preoperative Breast Ultrasonography: Association with Disease-free Survival of Patients with Primary Operable Invasive Breast Cancer.	E. Acad Radiol	25	1003-1009	2018
Yamauchi H, Okawa M, Yokoyama S, Nakagawa C, Yoshida R, Suzuki K, Nakamura S, Arai M.	High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan.	Breast Cancer Res Treat	172	679-687	2018
Yamauchi H, Nakagawa C, Kobayashi M, Kobayashi Y, Mano T, Nakamura S, Arai M.	Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.	Breast Cancer	25	141-150	2018
Yamauchi H, Takei J.	Management of hereditary breast and ovarian cancer.	Int J Clin Oncol	23	45-51	2018
Hirasawa A, Imoto I, Naruto T, Akahane T, Yamagami W, Nomura H, Masuda K, Susumu N, Tsuda H, Aoki D.	Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer.	Oncotarget	8	112258-112267	2017
Ueno M, Shiomi T, Mochizuki S, Chijiiwa M, Shimoda M, Kanai Y, Kataoka F, Hirasawa A, Susumu N, Aoki D, Okada Y.	ADAM9 is over-expressed in human ovarian clear cell carcinomas and suppresses cisplatin-induced cell death.	Cancer Sci	109	471-482	2018

Yoshihama T, Nomura H, Iwasa N, Kataoka F, Hashimoto S, Nanki Y, Hirano T, Makabe T, Sakai K, Yamagami W, Hirasawa A, Aoki D.	Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer.	Jpn J Clin Oncol	47	1019-1023	2017
Masuda K, Hirasawa A, Irie-Kunitomi H, Akahane T, Ueki A, Kobayashi Y, Yamagami W, Nomura H, Kataoka F, Tominaga E, Banno K, Susumu N, Aoki D.	Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer.	Jpn J Clin Oncol	47	401-406	2017
Yoshihama T, Hirasawa A, Nomura H, Akahane T, Nanki Y, Yamagami W, Kataoka F, Tominaga E, Susumu N, Mushiroda T, Aoki D.	UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan.	Jpn J Clin Oncol	47	170-174	2017
Adachi M, Banno K, Masuda K, Yanokura M, Iijima M, Takeda T, Kunitomi H, Kobayashi Y, Yamagami W, Hirasawa A, Kameyama K, Sugano K, Aoki D.	Carcinoma of the lower uterine segment diagnosed with Lynch syndrome based on MSH6 germline mutation: A case report.	J Obstet Gynaecol Res	43	416-420	2017
Machida Y, Shimauchi A, Okuma H, Tozaki M, Isobe S, Fukuma E.	Shear Wave Speed of the Lesion in Preoperative Breast Ultrasonography: Association with Disease-free Survival of Patients with Primary Operable Invasive Breast Cancer.	Acad Radiol		30029-1	2018

Shimauchi A, Machida Y, Maeda I, Fukuma E, Hoshi K, Tozaki M.	Breast MRI as a Problem-solving Study in the Evaluation of BI-RADS Categories 3 and 4 Microcalcifications: Is it Worth Performing?	Acad Radiol	25	288-296	2018
Sasaki M, Tozaki M, Kubota K, Murakami W, Yotsumoto D, Sagara Y, Ohi Y, Oosako S, Sagara Y.	Simultaneous whole-body and breast 18F-FDG PET/MRI examinations in patients with breast cancer: a comparison of apparent diffusion coefficients and maximum standardized uptake values.	Jpn J Radiol	36	122-133	2018
Tozaki M, Nakamura S, Kitagawa D, Iwase T, Horii R, Akiyama F, Arai M.	Ductal Carcinoma in situ Detected during Prospective MR Imaging Screening of a Woman with a BRCA2 Mutation: The First Case Report in Japan.	Magn Reson Med Sci	16	265-269	2017
Machida Y, Shimauchi A, Kuroki Y, Tozaki M, Kato Y, Hoshi K, Fukuma E.	Single focus on breast magnetic resonance imaging: diagnosis based on kinetic pattern and patient age.	Acta Radiol	58	652-659	2017
Yamauchi T, Espinosa Fernandez JR, Imamura CK, Yamauchi H, Jinno H, Takahashi M, Kitagawa Y, Nakamura S, Lim B, Krishnamurthy S, Reuben JM, Liu D, Tripathy D, Chen H, Takebe N, Saya H, Ueno NT.	Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer.	Oncotarget	9	6872-6882	2018

Hayashi N, Takahashi Y, Matsuda N, Tsunoda H, Yoshida A, Suzuki K, Nakamura S, Yamauchi H.	The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.	Clin Breast Cancer	18	e219-e229	2018
Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S.	Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a subgroup analysis of the JBCRG-C06 Safari study.	Curr Med Res Opin	34	49-54	2018
Tagawa N, Sugiyama E, Tajima M, Sasaki Y, Nakamura S, Okuyama H, Shimizu H, Sato VH, Sasaki T, Sato H.	Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer.	Cancer Chemother Pharmacol	80	841-849	2017
Yoshida A, Hayashi N, Suzuki K, Takimoto M, Nakamura S, Yamauchi H.	Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer.	J Surg Oncol	116	1021-1028	2017
Watanabe J, Ito Y, Ohsumi S, Mizutani M, Tashiro H, Sakurai K, Takahashi M, Saito T, Tsurutani J, Mukai H, Yoshinami T, Takao S, Yamamoto Y, Matsuoka T, Iwase H, Iwata H, Nakamura S, Saeki T.	Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study.	Invest New Drugs	35	791-799	2017

Matsuda N, Kida K, Ohde S, Suzuki K, Yamauchi H, Nakamura S, Tsunoda H.	Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy.	Breast Cancer	25	43-49	2017
Hayashi N, Iwamoto T, Qi Y, Niikura N, Santarpia L, Yamauchi H, Nakamura S, Hortobagyi GN, Pusztai L, Symmans WF, Ueno NT.	Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status.	J Cancer	8	1045-1052	2017
Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yamamoto Y, Ohno S, Toi M.	Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).	Breast Cancer Res Treat	163	545-554	2017
Sawada T, Akashi S, Nakamura S, Kuwayama T, Enokido K, Yoshida M, Hashimoto R, Ide T, Masuda H, Taruno K, Oyama H, Takamaru T, Kanada Y, Ikeda M, Kosugi N, Sato H, Nakayama S, Ata A, Tonouchi Y, Sakai H, Matsunaga Y, Matsutani A.	Digital volumetric measurement of mammographic density and the risk of overlooking cancer in Japanese women.	Breast Cancer	24	708-713	2017
Tozaki M, Nakamura S, Kitagawa D, Iwase T, Horii R, Akiyama F, Arai M.	Ductal Carcinoma in situ Detected during Prospective MR Imaging Screening of a Woman with a BRCA2 Mutation: The First Case Report in Japan.	Magn Reson Med Sci	16	265-269	2017
Fukushima Y.	[Genetic Counseling of HBOC and Japanese Organization of HBOC]	Gan To Kagaku Ryoho	44	107-110	2017

Takaoka M, Miki Y.	BRCA1 gene: function and deficiency.	Int J Clin Oncol	23	36-44	2018
Sunada S, Nakanishi A, Miki Y.	Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.	Cancer Sci	109	893-899	2018
Sato K, Koyasu M, Nomura S, Sato Y, Kita M, Ashihara Y, Adachi Y, Ohno S, Iwase T, Kitagawa D, Nakashima E, Yoshida R, Miki Y, Arai M.	Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.	Cancer Sci	108	2287-2294	2017